Ketamine: A Magic Remedy
The largest, longest study conducted on depression treatments, called the STAR*D trial, found that after people tried four antidepressants over the course of five years, about 70% of them were free of depressive symptoms. That’s a lot of trial and error to end at a place where 30% of patients don’t experience remission at all. The STAR*D trial ended in 2014, and despite a clear hole in the market–and a clear patient need–a golden age of new depression treatments still hasn’t arrived. The anesthetic ketamine could offer hope for people who don't have other depression treatment options. The most recent research on ketamine, as well as a statement from experts on its use published in April 2017, finds the drug works quickly, makes dramatic improvements in mood, and can work on people who haven’t gotten better with other depression treatments.
efficacy of repeated-dose intravenous ketamine for treatment-resistant depression”; Biological Psychiatry;
2. American Psychiatric Association (2000); Diagnostic and statistical manual of mental disorders: DSM-IV-TR;
4th; Washington, DC; New York. Task Force on DSM-IV; Text revision ed.
3. Autry AE1, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011); “NMDA
receptor blockade at rest triggers rapid behavioural antidepressant responses”; Nature; 475(7354); 91-95
4. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000); “Antidepressant
effects of ketamine in depressed patients”; Biological Psychiatry; 47(4); 351-354.
5. Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, Dursun SM (2008); “Glutamate and the neural basis of the
subjective effects of ketamine: a pharmaco-magnetic resonance imaging study”; Archives of General Psychiatry;
6. DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, Machado-Vieira R, Zarate CA
Jr (2010); “Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in
patients with treatment-resistant major depressive disorder”; Journal of Clinical Psychiatry; 71(12); 1605-1611
7. Duman RS, Monteggia LM (2006); “A Neurotrophic Model for Stress-Related Mood Disorders”; Biological
Psychiatry; 59(12); 1116-1127.
8. Garcia LS1, Comim CM, Valvassori SS, Réus GZ, Stertz L, Kapczinski F, Gavioli EC, Quevedo J (2009); “Ketamine
treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats”; Progress in
Neuropsychopharmacology and Biological Psychiatry; 33(3); 450-455.
9. Holcomb HH, Lahti AC, Medoff DR, Cullen T, Tamminga CA (2005); “Effects of noncompetitive NMDA receptor
blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia”;
Neuropsychopharmacology; 30(12); 2275-2282.
10. Homayoun H, Moghaddam B (2007); “NMDA receptor hypofunction produces opposite effects on prefrontal
cortex interneurons and pyramidal neurons”; The Journal of Neuroscience; 27(43); 11496-11500.
11. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS (2003); “The
epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)”;
JAMA; 289(23); 3095-3105
12. Larkin GL, Beautrais AL (2011); “A preliminary naturalistic study of low-dose ketamine for depression and
suicide ideation in the emergency department”; International Journal of Neuropsychopharmacology; 14(8);
13. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS (2010); “mTOR-Dependent
Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists”; Science; 329(5994); 959-
14. Mathew SJ, Murrough JW, Aan het Rot M, Collins KA, Reich DL, Charney DS (2010); “Riluzole for relapse
prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebocontrolled
continuation trial”; International Journal of Neuropsychopharmacology; 13(1); 71-82
15. Machado-Vieira R (2009); “Brain-derived neurotrophic factor and initial antidepression response to an Nmethyl-D-aspartate
antagonist”; J Clin Psychiatry; 70(12); 1662-1666.
16. Murrough JW, Perez AM, Mathew SJ, Charney DS (2011); “A case of sustained remission following an acutecourse of ketamine in treatment-resistant depression”; J Clin Psychiatry; 72(3); 414-415.
17. Manji HK, et al (2003); “Enhancing neuronal plasticity and cellular resilience to develop novel, improved
therapeutics for difficult-to-treat depression”; Biological Psychiatry; 53(8); 707-742.
18. Murrough JW, Iacoviello B, Neumeister A, Charney DS, Iosifescu DV (2011); “Cognitive dysfunction in
depression: Neurocircuitry and new therapeutic strategies”; Neurobiology of Learning and Memory; 96(4); 553-
19. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK (2008); “Cellular mechanisms
underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-
propionic acid receptors”; Biological Psychiatry; 63(4); 349-352.
20. Moghaddam B, Adams B, Verma A, Daly D (1997); “Activation of glutamatergic neurotransmission by
ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions
associated with the prefrontal cortex”; The Journal of Neuroscience; 17(8); 2921-2927.
21. Price JL, Drevets WC (2010); “Neurocircuitry of mood disorders”; Neuropsychopharmacology; 35(1); 192-
22. Price RB, Nock MK, Charney DS, Mathew SJ (2009); “Effects of intravenous ketamine on explicit and implicit
measures of suicidality in treatment-resistant depression”; Biol Psychiatry; 66(5); 522-526.
23. Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain
MM, Cook IA, Shelton RC, Lesser IM, Kornstein SG, Wisniewski SR (2011); “Combining Medications to Enhance
Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study”; The
American Journal of Psychiatry; 168(7); 689-701.
24. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori
PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006); “Acute and
longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report”; The
American Journal of Psychiatry; 163(11); 1905-1917.
25. Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E, Barrow R, Yeo R, Lauriello J, Brooks WM.
(2005); “Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS
study”; Am J Psychiatry; 162(2); 394-396.
26. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R (1996); “Adaptation of N-methyl-D-aspartate
(NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression”;
Pharmacopsychiatry; 29(1); 23-26.
27. Trullas R, Skolnick P (1990); “Functional antagonists at the NMDA receptor complex exhibit antidepressant
actions”; European Journal of Pharmacology; 185(1); 1-10.
28. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J (1997); “Metabolic
hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography
(PET) and *18F+fluorodeoxyglucose (FDG)”; European Neuropsychopharmacology; 7(1); 9-24.
29. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006); “A
randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression”; Arch Gen
Psychiatry; 63(8); 856-864.